Introduction {#S1}
============

According to the data provided by the North American Association of Central Cancer Registries (NAACCR), pancreatic cancer is the 12th most common cancer with the 5th worst prognosis in the United States. It is estimated that there will be 56,770 new cases of pancreatic cancer and 45,750 pancreatic cancer-related deaths in the United States in 2019. Compared to other common cancers, pancreatic cancer has not seen a significant improvement in patient outcomes, with a 9% 5-year relative survival ([@B40]). Surgery, radiation therapy and chemotherapy are still the main treatment options for pancreatic cancer, but there is now considerable effort in identifying better treatment strategies for pancreatic cancer, such as targeted therapy, immune therapy and potentially CRISPR/Cas9 directed gene therapy.

Currently CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9) is emerging as a powerful gene-editing tool with potential in precision medicine. CRISPR repetitive sequences were first observed by [@B16], with subsequent work performed by [@B17] proving that an endonuclease can be directed to cleave target DNA by a two-RNA structure. Since then, CRISPR/Cas9 technology has rapidly evolved, driving incredible progress in research and clinical applications. Compared to the other gene-editing technologies, such as meganucleases (MNs), zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), CRISPR/Cas9 technology has lower cost, higher efficiency and is less complex in its application ([@B30]).

Background of CRISPR/Cas9 {#S2}
=========================

CRISPR (clustered regularly interspaced short palindromic repeats) were first described in 1987 by [@B16] who identified highly conserved nucleotide sequences exhibiting a 14 bp dyad symmetry at the 3′-end flanking region of the isozyme-converting alkaline phosphatase (iap) gene in *Escherichia coli.* However, the function and biological importance of CRISPR sequences were not fully understood until 2007, when [@B5] exposed Streptococcus thermophilus to phage and sequenced the resultant phage-resistant variants. Analysis of the variant DNA revealed that the bacteria had gained new CRISPR spacers that were derived from the phage genome. The identification of CRISPR sequences in bacterial genomes subsequently led to the identification of a set of homologous genes referred to as CRISPR and associated (*cas*) genes that together comprise the CRISPR locus. The insertion of CRISPR-Cas in the genomes of bacteria infected with virus suggested that CRISPR-Cas may provide resistance against phages and that resistance to infection might be enhanced or decreased by inserting or deleting spacer-phage sequence.

[@B17] in 2012 were the first to demonstrate that the CRISPR-Cas system could produce a mature CRISPR RNA (crRNA) and base-paired *trans-*activating crRNA (tracrRNA) that together form a two-RNA hybrid structure. This two-RNA structure could guide CRISPR-associated protein Cas9 to specific DNA sequences and generate double-stranded (ds) breaks in target DNA. In 2013, [@B9] and [@B27] successfully edited the DNA sequences of the EMX1, PVALB, PPP1R12C genes in human and the Th gene in mouse using the CRISPR/Cas9 system. This was the first demonstration of the power of the CRISPR-Cas9 system to edit the genomes of eukaryotic cells. Since then, a wealth of research has improved the CRISPR/Cas9 gene editing tool's specificity, orthogonality and multiplexibility in various species, and has led to the development of new omics applications.

CRISPR/Cas9 technology has been rapidly promoted and applied in the: generation of animal models; gene function research; multiplexed mutations; and chromosome rearrangements. Compared to traditional gene editing tools such as MNs, ZFNs, TALENs and so on, CRISPR/Cas9 technology provides the advantage of lower cost, higher efficient and greater simplicity ([@B30]).

Application of CRISPR/Cas9 in Pancreatic Cancer {#S3}
===============================================

CRISPR/Cas9 Gene Editing in Pancreatic Cancer {#S3.SS1}
---------------------------------------------

An homologous guide RNA can guide the cas9 nuclease to target a specific site in the genome. When cas9 is guided to the target DNA sequence and there is a Protospacer Adjacent Motif (PAM) sequence downstream, it will cut both strands of the genome at that location. The cells then repair the break using two distinct mechanisms: (1) imprecisely by using the non-homologous end joining (NHEJ) repair pathway, which causes the insertion or deletion of bases; or (2) accurately by the homology-directed repair (HDR) pathway. Based on existing homologous DNA sequences, the HDR pathway can repair DNA damage accurately by mediating a strand-exchange process involving the provided DNA sequence as a repair template to insert a matching DNA sequence into the break. By inducing NHEJ or HDR, CRISPR/Cas9 knockouts or knockins can be achieved by deleting, replacing or adding genetic sequences.

CRISPR/Cas9 system is widely used in pancreatic cancer research to knock-out genes implicated in disease progression. [@B49] used CRISPR/Cas9 to knock out KDM6A in human Pancreatic ductal adenocarcinoma (PDAC) cell lines to demonstrate that KDM6A-deficient cells exhibit an aggressive phenotype. [@B31] and [@B6] showed that, CRISPR/Cas9-directed knock-out of ANXA1 in Mia PaCa2 cells, resulted in the secretion of fewer extracellular vesicles and a weak motile phenotype. After knock out of GALNT3 in Capan1 cells, [@B4] found that cells formed fewer tumorspheres, lost their ability to self-renewal, and migrate. [@B54] demonstrated that knock out of SphK1in PAN02 cells resulted in increased proliferation and migration. C1GALT1 was knocked out of PDAC cells by [@B8] with CRISPR/Cas9 technology, and the cells showed increased growth, migration, tumorigenicity, metastasis and expression of Tn and sTn. There are also some other researches in pancreatic cancer based on the same strategy by knocking out specific gene of pancreatic cancer cells, then observe the changes in different phenotypes ([Table 1](#T1){ref-type="table"}; [@B6]; [@B14]; [@B28]; [@B34]; [@B46]; [@B2]; [@B11]; [@B13]; [@B18]; [@B29]; [@B53]; [@B55]; [@B4]; [@B8]; [@B23], [@B24], [@B25]; [@B31]; [@B36]; [@B48]; [@B49]; [@B52]; [@B54]; [@B1]; [@B15]; [@B20], [@B21]; [@B43]). Collectively, these studies show that CRISPR/Cas9 is a very powerful gene editing tool for exploring the function of defined genes in cell signaling pathways, proliferation, migration, invasion and potentially chemotherapy resistance of pancreatic cancer. By using CRISPR/Cas9 technology to knock out target genes and characterize phenotypic changes, we can develop a better understanding of biological roles played by target genes, identify potential treatment targets and/or better treatment strategy for pancreatic cancer. But there is still a long way to go before CRISPR/Cas9 technology can be used as an effective treatment strategy in the clinic.

###### 

Recent researches of gene function in pancreatic cancer by CRISPR/Cas9 knockouts of pancreatic cancer cells.

  **sgRNA target**   **Cell lines**                                     **Effect**                                                                                       **References**
  ------------------ -------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------
  KDM6A              BxPC3, PANC1                                       proliferation↑, migration↑, invasion↑                                                            [@B49]
  ANXA1              MIA PaCa-2                                         migration↓, invasion↓, extracellular vesicles↓                                                   [@B31]; [@B6]
  SphK1 SphK2        PAN02                                              proliferation↑, migration↑, survival of mice↓ proliferation↓, migration↓, survival of mice↑      [@B54]
  GALNT3             Capan1                                             proliferation↓, migration↓                                                                       [@B4]
  C1galt1            KPC, KPCC                                          proliferation↑, migration↑, tumorigenicity↑, metastasis↑                                         [@B8]
  ARID1A             HPDE                                               H2K27ac marks↑                                                                                   [@B48]
  GPRC5a             MIA PaCa-2, TB32047                                proliferation↓, migration↓, chemotherapy resistance↓                                             [@B23]
  ECT2               MIA PaCa-2                                         proliferation↓, migration↓                                                                       [@B24]
  ATG12              MIA PaCa-2, AR42J                                  expression of duct cell markers↑, expression of acinar cell markers↓                             [@B52]
  KRAS               A13,8988T, PANC1, KP-4, MM1402, PACO9, PACO19      exhibit PI3K dependence                                                                          [@B29]
  HuR                MIA PaCa-2                                         apoptosis↑, unable to engraft tumors *in vivo*                                                   [@B18]
                     Hs 776T                                            unable to engraft tumors *in vivo*                                                               
                     HCT116                                             proliferation↓                                                                                   
  Rab11-FIP4         PANC-1                                             proliferation↓, invasion↓, metastasis↓                                                           [@B13]
  IRAK4              PANC-1, Pa01c                                      anchorage-independent (AI) growth↓                                                               [@B55]
  CYR61              MIA PaCa-2, PANC1                                  hENT1 and hCNT3 expression↑, cellular uptake of gemcitabine↑, gemcitabine-induced apoptosis↑     [@B14]
  MUC16              Capan1                                             expression of Thomsen-Friedenreich (TF/T) and Thomsen-nouvelle (Tn) carbohydrate antigens↓       [@B28]
  FOXA2              PANC-1                                             tumorigenicity↑, aggressiveness↑                                                                 [@B46]
  GCNT3              MIA PaCa, BxPC-3, PANC-1                           proliferation↓, spheroid formation↓                                                              [@B34]
  CTTN               PANC-1, BxPC-3                                     migration↓, invasion↓                                                                            [@B43]
  CRABP-II           PANC-1                                             migration↓, invasion↓, expression of interleukin 8 (IL-8), MMP-2 and MMP-14↓                     [@B53]
  HO-1               Capan-1                                            Under hypoxia, proliferation↓, sensitivity to gemcitabine↑                                       [@B1]
  WNT5B              PANC-1                                             migration↓, invasion↓                                                                            [@B11]
  CDH17              Panc02-H7                                          Proliferation, colony formation and motility↓                                                    [@B25]
  EI24               MIA PaCa-2                                         Proliferation↓                                                                                   [@B15]
  HO1                CD18/HPAF, COLO 357, Capan-1, Mia PaCa-2           under hypoxia, proliferation↓, sensitive to gemcitabine↑                                         [@B1]
  IL2RG              TB32043, bkpc58                                    Tumor growth in mice↓, JAK3 expression in orthotopic tumors↓                                     [@B2]
  HIF-1α             BxPC-3                                             Metastasis↓                                                                                      [@B20]
  MEKK3              Panc-1, AsPC1                                      EMT and cell migration↓, tumor growth↓, mice overall survival↑                                   [@B36]
  ERBB2              HPAFII, CAPAN1, Mia PaCa-2 (all ERBB2-amplified)   ERBB2 signaling, colony formation, anchorage-independent growth and tumor xenograft formation↓   [@B21]

↑, up-regulation; and ↓, down-regulation.

Gene knockins by CRISPR/Cas9 are also quite important for exploring gene functions in tumorigenesis and development and commonly used for building specific gene expression stem cells and animal models in recently years ([@B51]; [@B32]; [@B26]; [@B19]). But due to the complicated procedure and time consumption, it is still more common to generate gene expressing cells by building gene expression vectors and transducing the vector into cells via retrovirus or lentivirus in pancreatic cancer research ([@B21]; [@B38]; [@B50]).

CRISPR Pooled Library Screening in Pancreatic Cancer {#S3.SS2}
----------------------------------------------------

Using a sgRNA library to perform loss-of-function (LoF) phenotypic screens is a powerful way to identify novel protein functions in specific growth conditions. The main strategy of CRISPR pooled library screening involves the use of thousands of plasmids in one CRISPR pooled library, with each plasmid containing an sgRNA targeting a specific gene. The sgRNAs first needs to be delivered into a sufficient number of cells via lentivirus or retrovirus transduction. The transduced cells are then grown under specific conditions to select a phenotype of interest. After the selection, the genomic DNA is isolated from the cells, and next-generation sequencing (NGS) performed. The NGS data are then mapped to a pre-complied library comprising the gene-specific gRNAs and the results analyzed by computational tool such as MAGeCK (Model-based Analysis of Genome-wide CRISPR-Cas9 Knockout) ([@B22]). Genes responsible for the observed phenotype are then identified by comparing control and selected gRNAs.

Several studies have now used CRISPR pooled library screening in pancreatic cancer cells ([Table 2](#T2){ref-type="table"}; [@B42]; [@B47]; [@B44]; [@B3]; [@B37]). [@B3] transduced PANC-1-cas9 cells with human sgRNA library Brunello and selected the cells with 100 nM gemcitabine for 6 days. PSMA6 was identified as a top hit after comparing NGS results obtained for gemcitabine selected samples and control samples. PSMA6 inhibition was subsequently shown to result in apoptosis and reduced spheroid formation. In [@B42], a TKO gRNA library was transduced into HPAF-II-Cas9 cells, and cells screened at different time points to identify the set of fitness genes required for proliferation. They used the BAGEL algorithm ([@B12]) to calculate a log Bayer factor (BF) for each gene. This analysis identified several core components of the Wnt pathway, including WLS, CTNNB1, TCF7L2, LRP5, and PORCN, and 3 Frizzled (FZD) receptors and Wnts encoding genes, FZD5, WNT7B, WNT10A, as essential genes for HPAF-II cell proliferation. These results were subsequently validated in AsPC-1 and PaTU8988S cell lines, identifying the Wnt pathway as an important mediator of pancreatic cancer cell proliferation. These screen results also revealed that the proliferation and/or survival of RNF43-mutant PDAC cells are selectively dependent on Wnt-β-catenin signaling. [@B47] also performed genome scale CRISPR-Cas9 knockout screens in PATU8902 and PATU8988T cell lines to identify genes capable of promoting proliferation or survival in the context of MAPKi by deletion. They transduced the GeCKOv2 library into PATU8902 cells, and Avana library into PATU8988T cells. PATU8902 cells were treated with MEK1/2 inhibitor trametinib 100 nM and PATU8988T cells were treated with 10 nM trametinib. Both cell lines were treated with trametinib for 14 days. Genomic DNA was then isolated and NGS performed. CIC and ATXN1L were identified by comparative analysis, indicating that loss of both CIC and ATXN1L can reduce sensitivity to trametinib treatment *in vivo*.

###### 

Recent researches of CRISPR pooled library screening in pancreatic cancer.

  **Hit genes**             **Effect**                              **Cell line**                **Library**                                                      **Gene/sgRNA number**   **Selection condition**                                                     **References**
  ------------------------- --------------------------------------- ---------------------------- ---------------------------------------------------------------- ----------------------- --------------------------------------------------------------------------- ----------------
  PSMA6                     apoptosis↑, spheroid formation↓         PANC-1                       Human sgRNA library Brunello (addgene No. 73178)                 19114/76441             100 nM gemcitabine for 6 days                                               [@B3]
  Wnt pathway genes, FZD5   Proliferation↓                          HPAF-II, AsPC-1, PaTu8988S   Toronto KnockOut (TKO) CRISPR Library (addgene No. 1000000069)   17232/91320             different time point (Day 15, 27, 31, 35)                                   [@B42]
  CIC, ATXN1L               sensitivity to trametinib↓              PATU8902                     GeCKOv2 library (addgene No. 1000000049)                         19050/123411            100 nM trametinib for 14 days                                               [@B47]
                                                                    PATU8988T                    Avana library [@B10]                                             18675/110257            10 nM trametinib for 14 days                                                
  CENPE, RRM1               sensitivity to trametinib↑              PDX366                       Nuclear proteins gRNA sub-pool library (addgene No. 51047)       7114/73151              MEK and CENPE inhibitor treatment in 6--8-week-old mail athymic nude mice   [@B44]
  DCK, DCTPP1               sensitivity to NUC-1031, gemcitabine↓   Mia PaCa-2, A2780            GeCKOv2 library (addgene No. 1000000049)                         19050/123411            15 nM gemcitabine or 65 nM NUC-1031 for 14 days or 21 days                  [@B37]

↑, up-regulation; and ↓, down-regulation.

These studies successfully demonstrate that novel gene functions can be identified using CRISPR pooled library screening with specific selection conditions, thereby providing a very powerful methodology for identifying therapeutic vulnerabilities in pancreatic cancer cells and pointing the way toward new treatment strategies. But there are also several factors that can affect the accuracy of the screening results. Based on different size of libraries, different number of cells are required to be transduced for maintaining the coverage of the libraries. Weak selection conditions may provide more comprehensive results, but will also produce false positive which may not be causative in phenotypic changes. Different selection methods may also drive experimental variability. The deep sequencing quality and the selection of data analysis tools will also play very important roles in screening accuracy. Therefore, results still need to be validated using orthogonal methods.

Current Status of CRISPR/Cas9 Gene Therapy for Pancreatic Cancer {#S3.SS3}
----------------------------------------------------------------

In pancreatic cancer gene therapy, there are several current developments including gene-based tumor cell sensitization to chemotherapy, vaccination, and adoptive immunotherapy ([@B35]). But recently the CRISPR/Cas9 genome editing method has been utilized in several pancreatic cancer studies due to its safety and efficacy. CRISPR/Cas9 gene therapy could be potentially used both *ex vivo* and *in vivo*. In *ex vivo* therapy, cells could be isolated and modified outside of the body, and then transplanted back into the body. In *in vivo* therapy, genetic materials could be directly injected into the body ([@B41]). [@B7] built *in vivo* pancreatic cancer models via retrograde pancreatic ductal injection of either adenoviral-Cre and lentiviral-Cre vectors. This technique could establish new therapies for pancreatic cancer. Accordingly, CRISPR/Cas9 technology is providing great hope for the treatment of monogenic diseases, degenerative diseases and HIV infection, and several CRISPR/Cas9 clinical trials have been performed, but there is still a long way to go before the CRISPR/Cas9 technique is used to treat pancreatic cancer patients. Several challenges still need to be considered. For example, which crucial gene(s) should be targeted? And the accuracy, efficiency and safety need to be increased to meet the requirement of clinical application.

Limitations of the Crispr/Cas9 Application {#S4}
==========================================

CRISPR/Cas9 is widely applied not only in pancreatic cancer research, but also other cancer settings to further our understanding of disease progression, identify mechanisms of drug resistance and to uncover potential therapeutic vulnerabilities. However, there are still some limitations to this technology that need to be considered before CRISPR/Cas9 is used in the clinical practice. Potential off-target effect are a major concern and need to be minimized to ensure safety. Considerable effort has been made to reduce off-target effects. [@B33] combined the D10A mutant nickase Cas9 (Cas9n) with a pair of offset sgRNAs which are complementary to opposite strands of the target site. This approach improved the specificity of CRISPR/Cas9 editing without sacrificing on-target cleavage efficiency. [@B39] used Cas9(D10A) or Cas9(H840A) to perform AR-A and AR-B gene editing in mouse fibroblast cells. T7EN cleavage assay and TA cloning were performed to detect the modification of the AR gene, and off-target effects were not found. [@B45] demonstrated that dimeric RNA-guided *Fok*I Nucleases (RFNs) could recognize extended sequences and edit endogenous genes with high efficiencies.

Conclusion and Outlook {#S5}
======================

Compare to the other gene-editing technologies, CRISPR/Cas9 technology involves lower costs, higher efficiency and simplicity of use. It is widely used to characterize gene function(s) under specific selection conditions and is gaining traction in pancreatic cancer research. But there is still a long way before this technology can be used as a selective gene therapy in the clinics. Improving the specificity of cas9 gene editing, reducing off-target effects and increasing the efficiency of cell transduction and cell targeting are all important challenges that need to be overcome. As a maturing gene editing technology, CRISPR/Cas9 represents a "game changer" for scientific research and an exciting targeted therapy for pancreatic cancer.
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